Market Intelligence, Clinical Progress, and High-Purity Reagents for Pruritic and Dermatological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL31RA/IL31R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Alpha Subunit) | IL31RA ECD-Fc Fusion Protein; Human, HEK293 Expressed, >95% Purity, Endotoxin <1 EU/μg, Sequence Verified. Theoretical MW confirmed (glycosylated). | View IL31RA Products |
| Gene Delivery (IL31RA) | IL31RA Promise-ORF / Lentivirus; Full-length ORF with Puromycin resistance marker for stable cell line construction, Titer >10^8 TU/mL. | View IL31RA Products |
| Co-Receptor (Beta Subunit) | OSMR ECD-Fc Fusion Protein; Essential heterodimeric partner, Human, HEK293 Expressed, >95% Purity, Sequence Verified for complex formation assays. | View OSMR Products |
| Ligand | IL31 Recombinant Protein; Human, HEK293 Expressed, Native glycosylation, High purity for competitive binding and activation assays. | View IL31 Products |
| Benchmark Ab | Anti-IL31RA (Nemolizumab Sequence); Recombinant positive control (IgG4 or IgG1) for assay calibration. | View IL31RA Products |
| Validator | IL31RA siRNA Set; Three target-specific sequences plus scrambled control; for knockdown verification and specificity controls. | View IL31RA Products |
| Related Target A | IL4R (IL4Rα); Master regulator of Th2 inflammation, synergistic pathway for combination therapy screening. | View IL4R Products |
| Related Target B | TSLPR (CRLF2); Thymic stromal lymphopoietin receptor, upstream modulator of itch and allergic inflammation. | View TSLPR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimeric Receptor Complex (IL31RA/OSMR) Formation | Matched human IL31RA and OSMR ECD-Fc proteins expressed in HEK293 to ensure compatible glycosylation patterns for native heterodimer assembly in SPR/BLI. |
| Cross-Species Evaluation (Human/Cyno/Mouse) | Ortholog proteins available with >95% purity and strictly verified theoretical MW; HEK293 expressed for native glycosylation. |
| Ligand Blockade Confirmation | High-activity IL31 protein (HEK293) for competitive binding assays; IL31RA-Fc enables direct SPR competition kinetics. |
| Lack of Positive Controls | Clinical Benchmark Antibodies (Nemolizumab biosimilar sequence) included for assay standardization. |
| False Positives / Off-Target Binding | Validated siRNA set included for specificity checks; knockdown confirmation in cellular assays (primary keratinocyte or HaCaT). |
| Agonism vs Antagonism Risk | Full-length Lentivirus ORF available for cell-based pSTAT reporter assays to confirm pure antagonism. |
Live IL31RA/IL31R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL31RA/IL31R therapeutics is intensifying. First-generation therapies like Nemolizumab (anti-IL31RA, developed by Chugai/Galderma) have established clinical utility for pruritus associated with atopic dermatitis and prurigo nodularis. The next wave of R&D is targeting optimized dosing profiles, bispecific formulations (e.g., IL31 x IL4), and expanded indications including chronic spontaneous urticaria, cholestatic pruritus, and chronic kidney disease–associated itch. Combination strategies with IL-4/IL-13 axis inhibitors (e.g., dupilumab) or TSLP blockade are also being explored to address severe, refractory atopic disease. As the modality landscape evolves from monoclonal antibodies to bispecifics and small molecules, the demand for high-purity, properly folded antigens and functional cell-based assays continues to grow.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-IL31RA mAb (Nemolizumab class) | Chugai, Galderma, Menarini | Atopic Dermatitis, Prurigo Nodularis, Chronic Spontaneous Urticaria | Ligand competition & epitope binning (need monomeric and heterodimeric ECD-Fc) |
| Anti-OSMR mAb (Vixarelimab) | Kiniksa | Prurigo Nodularis, Atopic Dermatitis | Heterodimer disruption assay (need both IL31RA and OSMR proteins) |
| Anti-IL31 mAb (ligand neutralization) | Galderma, Toray | Atopic Dermatitis, Prurigo Nodularis | Ligand binding competition assay (requires IL31RA ECD-Fc + IL31 protein pair) |
| Bispecific (IL31 x IL4) | Preclinical | Severe Atopic Dermatitis | Dual-target binding confirmation (need both IL31RA and IL4Rα antigens) |
| Small Molecule Antagonist | Early Discovery | Topical Pruritus | Selectivity vs. OSMR homodimer (requires OSMR protein panel for counter-screening) |